FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

OIPE IAP72 OCT 18 2005 PATENT & TRADEMARK OFFICE

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
JE	*	08/584,040	01/11/96	Pavco et al.			
	*	08/878,640	07/19/97	Usman et al.			
	*	09/205,520	12/03/98	Sullenger et al.			
	*	09/301,511	04/28/99	Beigleman et al.			
	*	09/371,772	08/10/99	Pavco et al.			
	*	09/476,387	12/30/99	Beigelman et al.			
	*	09/708,690	11/07/00	Pavco et al.			
	*	09/740,332	12/18/00	Blatt et al.			
	*	09/800,594	03/06/01	Usman and McSwiggen			
	*	09/870,161	05/29/01	Pavco et al.			
	*	09/877,526	06/08/01	Usman et al.			
	*	09/918,728	07/31/01	Beigelman et al.			
	*	10/138,674	05/03/02	Pavco et al.			
	*	10/417,012	04/16/03	McSwiggen et al.			
	*	10/422,704	04/24/03	McSwiggen et al.			
JE	*	10/652,791	08/29/03	McSwiggen et al.			

EXAMINER	/Janet Epps Ford/	DATE CONSIDERED	11/25/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

JE	*	10/683,990	10/10/03	McSwiggen et al.			
	*	10/726,236	12/02/03	Lockridge et al.			
	*	10/780,447	02/13/04	Vargeese et al.			
	*	10/826,966	04/16/04	McSwiggen et al.			
	*	60/005,974	10/26/95	Pavco et al.			
	*	60/101,174	09/21/98	Hartmann et al.			
	*	60/292,217	05/18/01	Adamic et al.			
	*	60/306,883	07/20/01	Vargeese et al.			
	*	60/311,865	08/13/01	Vargeese et al.			
	*	60/362,016	03/06/02	Matulic-Adamic et al.			
	*	60/386,782	06/06/02	Beigelman et al.			
	*	US 2002/0137210	08/09/01	Churikov			09/26/02
	*	US 2003/0077829	04/30/02	MacLachlan			04/24/03
	*	US 2003/0190635	07/25/02	McSwiggen et al.			10/09/03
JE	*	US 2003/0206887	09/16/02	Morrissey et al.			11/06/03

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

EXAMINER	/Janet Epps Ford/	DATE CONSIDERED	11/25/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	**Applicant:** McSwiggen et al.	
		Filing Date: October 10, 2003	**Group:** 1635

JE	*	4,987,071	01/22/91	Cech et al.				
	*	5,108,921	04/28/92	Low et al.				
	*	5,270,163	12/14/93	Gold et al.				
	*	5,359,051	10/25/94	Cook et al.				
	*	5,416,016	05/16/95	Low et al.				
	*	5,475,096	12/12/95	Gold et al.				
	*	5,525,468	06/11/96	McSwiggen et al.				
	*	5,589,332	12/31/96	Shih et al.				
	*	5,631,359	05/20/97	Chowrira et al.				
	*	5,741,679	04/21/98	George et al.				
	*	5,807,718	09/15/98	Joyce et al.				
	*	5,834,186	11/10/98	George et al.				
	*	5,849,902	12/15/98	Arrow et al.				
	*	5,871,914	02/16/99	Nathan et al.				
	*	5,968,909	10/19/99	Agrawal et al.				
	*	5,989,912	11/23/99	Arrow et al.				
	*	6,127,173	10/03/00	Eckstein et al.				
	*	6,159,714	12/12/00	Usman et al.				
JE	*	6,168,778	01/02/01	Janjic et al.				

EXAMINER	/Janet Epps Ford/	DATE CONSIDERED	11/25/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	6,235,886	05/22/01	Manoharan et al.				
	*	6,346,398	02/12/02	Pavco et al.				
	*	6,350,934	02/26/02	Zwick et al.				
	*	6,395,492	05/28/02	Manoharan et al.				
	*	6,566,127	05/20/03	Pavco et al.				

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	*	0 360 257	02/28/90	EP (Hampel et al.)				
	1.	1 325 955	07/09/03	EP (Klippel-Giese et al.)				
	2.	08208687	08/08/96	JP (Hotoda et al.)				
	*	88/09810	12/15/88	WO (Tullis et al.)				
	*	90/12096	10/18/90	WO (Low et al.)				
	*	93/12569	04/29/93	WO (Draper et al.)				
	*	93/23057	11/25/93	WO (Thompson et al.)				
	*	94/11499	05/26/94	WO (Ullrich et al.)				
	*	94/21679	09/29/94	WO (Kendall et al.)				

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	94/21791	09/29/94	WO (Bergmann et al.)				
	*	95/04142	02/09/95	WO (Robinson et al.)				
	*	95/04818	02/16/95	WO (Draper et al.)				
	*	95/11304	04/27/95	WO (Usman et al.)				
	*	95/13380	05/18/95	WO (Draper et al.)				
	*	95/21868	08/17/95	WO (Rockwell and Goldstein)				
	*	95/23225	08/31/95	WO (Stinchcomb et al.)				
	*	96/22689	08/01/96	WO (Pyle et al.)				
	*	97/00957	01/09/97	WO (Patterson-Winston et al.)				
	*	97/15662	05/01/97	WO (Pavco et al.)				
	3.	97/21808	06/19/97	WO (Robinson)				
	*	98/27104	06/25/98	WO (Breaker et al.)				
	*	98/28317	07/02/98	WO (Matulic-Adamic et al)				
	*	98/43993	10/08/98	WO (Breaker et al.)				
	*	98/58058	12/23/98	WO (Ludwig & Sproat)				
	*	99/04819	02/04/99	WO (Klimuk)				
	*	99/05094	02/04/99	WO (Beigelman et al.)				
	*	99/16871	04/08/99	WO (Eckstein et al.)				
	*	99/17120	04/08/99	WO (Davis and Bishop)				

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	99/29842	06/17/99	WO (Sullenger et al.)				
	*	99/55857	11/04/99	WO (Beigelman et al.)				
	*	99/63116	12/09/99	WO (Storella et al.)				
	*	99/66063	12/23/99	WO (Manoharan et al.)				
	4.	00/03683	01/27/00	WO (Boey et al.)				
	*	00/24931	05/04/00	WO (Nathan and Ellington)				
	*	00/26226	05/11/00	WO (Breaker et al.)				
	*	00/73416	12/07/00	WO (Labarbera et al.)				
	*	01/32920	05/10/01	WO (Pappa)				
	*	01/96584	12/20/01	WO (Mushegian et al.)				
	5.	01/097850	12/27/01	WO (Siemeister et al.)				
	6.	02/07747	01/31/02	WO (King)				
	7.	02/10378	02/07/02	WO (Cowsert et al.)				
	8.	02/087541	11/07/02	WO (MacLachlan)				
	*	02/094185 (PCT/US02/15876)	11/28/02	WO (Beigelman et al.)				
	9.	03/063904	07/07/03	WO (Koninckx et al.)				
	10.	03/068797	08/21/03	WO (Rossi et al.)				
	11.	03/070887	08/28/03	WO (McSwiggen et al.)				
	12.	03/070896	08/28/03	WO (McSwiggen et al.)				

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	**Applicant:** McSwiggen et al.	
		Filing Date: October 10, 2003	**Group:** 1635

	13.	03/070910	08/28/03	WO (McSwiggen et al.)				
	14.	03/080638	10/02/03	WO (Lacasse et al.)				
	15.	04/009769	01/29/04	WO (Tolentino et al.)				
	16.	04/043977	05/27/04	WO (Prakush et al.)				
	17.	04/072261	08/26/04	WO (Li et al.)				
	*	PCT/US02/17674	05/29/02	WO (Pavco et al.)				
	*	PCT/US03/05022	02/20/03	WO (McSwiggen et al.)				
	18.	PCT/US04/13456	04/30/04	WO (Vargeese et al.)				
	19.	PCT/US04/16390	05/24/04	WO (McSwiggen et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	*	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," Science 271:1410-1413 (1996)
	*	Aiello et al., "Suppression of Retinal Neovascularization *in vivo* by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins," Proc. Natl. Acad. Sci. USA 92: 10457-10461 (1995)
	20.	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," Oligonucleotides, 13:303-312 (2003)
	*	Antopolsky et al., "Peptide-Oligonucleotide Phosphorothioate Conjugates with Membrane Translocation and Nuclear Localization Properties," Bioconjugate Chem. 10:598-606 (1999)
	*	Arap et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," Science 279:377-380 (1998)

EXAMINER	DATE CONSIDERED
	11-25-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," Biochemistry 34:6504-6512 (1995)
	*	Bartel and Szostak, "Isolation of New Ribozymes from a Large Pool of Random Sequences," Science 261:1411-1418 (1993)
	21.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," *Eur. J. Biochem.*, 142(29):291-298 (1984)
	*	Beaudry and Joyce, "Directed Evolution of an RNA Enzyme," Science 257:635-641 (1992)
	*	Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," EBMO J. 12:2567-2574 (1993)
	*	Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed clevage and ligation reactions," Genes & Development 6:129-134 (1992)
	*	Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the *Tetrahymena* Ribozyme," Biochemistry 35:648-568 (1996)
	*	Blesch, "Delivery of Neurotrophic Factors to Neuronal Targets: Toward Gene Therapy in the CNS," Drug News & Perspectives 13:269-280 (2000)
	*	Bongartz et al., "Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide," *Nucleic Acids Research* 22:4681-4688 (1994)
	*	Bonora et al., "Biological Properties of Antisense Oligonucleotides Conjugated to Different High-Molecular Mass Poly(ethylen glycols)," Nucleosides & Nucleotides 18:1723-1725 (1999)
	*	Bonora et al., "Synthesis and Characterization of High-Molecular Mass Polyethylene Glycol-Conjugated Oligonucleotides," Bioconjugate Chem. 8:793-797 (1997)
	*	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," TIBTECH 12:268-275 (1994)
	*	Breaker et al., "A DNA enzyme with Mg^2-dependent RNA phosphoesterase activity," Chemistry & Biology 2(10):655-660 (1995)

EXAMINER	DATE CONSIDERED
Janet L. Epps-Ford	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	**Applicant:** McSwiggen et al.	
		Filing Date: October 10, 2003	**Group:** 1635

	*	Breaker, "Are engineered proteins getting competition from RNA?" Current Opinion in Biotechnology 7:442-448 (1996)
	*	Breaker, "Catalytic DNA: in training and seeking employment," *Nature Biotechnology* 17:422-423 (1999)
	*	Brogniez et al., "Fluorescence of Experimented Endometriosis in Rabbits, Using Tamoxifen-eosin Association," Human Reproduction 10:927-931 (1995)
	*	Buckwold et al., "Effects of a Naturally Occurring Mutation in the Hepatitis B Virus Basal Core Promoter on Precore Cene Expression and Viral Replication," *Journal of Virology,* 5845-5851 (1996)
	*	Carter, "Adeno-Associated Virus Vectors," Curr Opi. Biotech. 3:533-539 (1992)
	*	Cebon et al., "New DNA Modification Strategies Involving Oxime Formation," Aust. J. Chem. 53:333-339 (2000)
	*	Cech, "Ribozymes and Their Medical Implications," JAMA 260:3030-3034 (1988)
	*	Chaloin et al., "Design of Carrier Peptide-Oligonucleotide Conjugates With Rapid Membrane Translocation and Nuclear Localization Properties," BBRC 243:601-608 (1998)
	*	Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," Nucleic Acids Research 23(20):4092-4096 (1995)
	*	Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," Nature 354:320-322 (1991)
	*	Christoffersen and Marr, "Riobozymes as Human Therapeutic Agents," J. Med. Chem. 38:2023-2037 (1995) (also referred to as Christofferson and Marr)
	*	Christoffersen et al., "Application of computational techologies to ribozyme biotechnology products," Journal of Molecular Structure (Theochem) 311:273-284 (1994) (maybe referred to as Christofferson)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Chun et al., "Effect of infusion of vasoactive intestinal peptide (VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic cuprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats," *Neuroscience Letters* 257:135-138 (1998)
	*	Cole et al., "Activation of RNase L by 2',5'-Oligoadenylates," The Journal of Biological Chemistry, 272:31, 19187-19192 (1997)
	*	Collins and Olive, "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From *Neurospora* VS RNA," Biochemistry 32:2795-2799 (1993)
	*	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," Advances in Pharmacology 40:1-49 (1997)
	*	Crooke, "Antisense Therapeutics," Biotechnology and Genetic Engineering Reviews 15:121-157 (1998)
	*	Crooke, "Progress in Antisense Technology: The End of the Beginning," Methods in Enzymology 313:3-45 (1999)
	*	Cummings and Metcalf, "Effect of Surgically Induced Endometriosis on Pregnancy and Effect of Pregnancy and Lactation on Endometriosis in Mice[1]" P.S.E.B.M. 212:332-337 (1996)
	*	Cummings et al., "Promotion of Endometriosis by 2,3, 7, 8-Tetrachlorodibenzo-*p*-dioxin in Rats and Mice: Time-Dose Dependence and Species Comparison[1,2]," Toxicology and Applied Pharmacology 138:131-139 (1996)
	*	d'Aldin et al., "Antisense oligonucleotides to the GluR2 AMPA receptor subunit modify excitatory synaptic transmission in vivo," *Molecular Brain Research* 55:151-164 (1998)
	*	D'Hooghe et al., "The Cycle Pregnancy Rate is Normal in Baboons with Stage I Endometriosis but Decreased in Primates with Stage II and Stage III-IV Disease," Fertility and Sterility 66:809-813 (1996)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of *in Vitro* Reaction Rates and Products," J. Mol. Biol. 256:31-49 (1996)
	*	Defrancq and Lhomme, "Use of an Aminooxy Linker for the Functionalization of Oligodeoxyribonucleotides," Bioorganic & Medicinal Chem. Lett. 11:931-933 (2001)
	*	Delihas et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," Nature Biotechnology 15:751-753 (1997)
	*	Donnez et al., "Vascular Endothelial Growth Factor (VEGF) in Endometriosis," Human Reproduction 13:1686-1690 (1998)
	*	Dreyfus, "Restriction Ribozymes?" Einstein Quarterly Journal of Biology and Medicine 6:92-93 (1988)
	*	Dryden et al., "The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus," *Journal of Endocrinology* 157:169-175 (1998)
	*	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," Proc. Natl. Acad. Sci. USA 89:504-508 (1992)
	*	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," Nature 365:566-568 (1993)
	*	Fasciani et al., "High Concentrations of the Vascular Endothelial Growth Factor and Interleukin-8 in Ovarian Endometriomata," Molecular Human Reproduction 6:50-54 (2000)
	*	Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA," Gene 82:53-61 (1989)
	*	Ferrara, "Vascular Endothelial Growth Factor," *Trends Cardiovasc Med* 3:244-250 (1993)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Filion and Phillips, "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells," *Biochimica et Biophysica Acta* 1329:345-356 (1997)
	*	Findeis, "Stepwise Synthesis of a GalNAc-containing Cluster Glycoside Ligand of the Asialoglycoprotein Receptor," Int. J. Peptide Protein Res. 43:477-485 (1994)
	*	Folkman and Shing, "Angiogenesis," J. Biol. Chem. 267:10931-10934 (1992)
	*	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" Journal of the National Cancer Institute 82:4-6 (1990)
	*	Fong *et al.*, "Role of the Flt-1 Receptor Tyrosine Kinase in Regulating the Assembly of Vascular Endothelium," 1995 *Nature* 376, 66 **Corrected from specification**
	*	Forster and Altman, "External Guide Sequences for an RNA Enzyme," Science 249:783-786 (1990)
	*	Fox, "Targeting DNA with Triplexes," *Current Medicinal Chemistry* 7:17-37 (2000)
	*	Genbank Accession No. AB020693
	22.	Genbank Accession No. AC006530
	*	Genbank Accession No. AF037412
	*	Genbank Accession No. AF100308.1
	*	Genbank Accession No. AJ430458
	23.	Genbank Accession No. BC001422
	24.	Genbank Accession No. BC007255
	25.	Genbank Accession No. BC007789
	26.	Genbank Accession No. BT007182

EXAMINER	DATE CONSIDERED
Janet L. Epps-Ford	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	27.	Genbank Accession No. BT008273
	28.	Genbank Accession No. BX248389
	*	Genbank Accession No. D00239
	*	Genbank Accession No. D11168
	*	Genbank Accession No. D50483.1
	*	Genbank Accession No. K02121
	*	Genbank Accession No. L24917
	*	Genbank Accession No. L38318
	*	Genbank Accession No. M16248
	*	Genbank Accession No. M31724
	*	Genbank Accession No. NC_001345
	*	Genbank Accession No. NC_001347
	*	Genbank Accession No. NC_001353
	*	Genbank Accession No. NC_001563
	*	Genbank Accession No. NC_001781
	*	Genbank Accession No. NC_004718
	*	Genbank Accession No. NM_001285
	*	Genbank Accession No. NM_001982
	*	Genbank Accession No. NM_002592.1
	29.	Genbank Accession No. NM_002632

EXAMINER	DATE CONSIDERED
[signature]	1-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Genbank Accession No. NM_002667
	*	Genbank Accession No. NM_002737
	*	Genbank Accession No. NM_003219
	*	Genbank Accession No. NM_004283
	*	Genbank Accession No. NM_004448
	*	Genbank Accession No. NM_005228
	*	Genbank Accession No. NM_005235
	30.	Genbank Accession No. S72960
	*	Genbank Accession No. S82227
	*	Genbank Accession No. U51188
	*	Genbank Accession No. U86046
	*	Genbank Accession No. X01087
	*	Genbank Accession No. X02316
	*	Genbank Accession No. X07203
	*	Genbank Accession No. X51602
	31.	Genbank Accession No. X54936
	*	Genbank Accession No. X60667
	*	Genbank Accession No. XM_015620

EXAMINER	DATE CONSIDERED
Janet F. Epps-Ford	12-7-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Genbank Accession No. XM_033884
	*	Genbank Accession No. XM_067723
	*	Ghirnikar et al., "Chemokine inhibition in rat stab would brain injury using antisense oligodeoxynucleotides," Neuroscience Letters 247:21-24 (1998)
	*	Gitay-Goren et al., "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-associated Heparin-like Molecules," *The Journal of Biological Chemistry* 267:6093-6098 (1992)
	*	Godwin et al., "The Synthesis of Biologically Active Pteroyloligo-γ-L-Glutamates (Folic Acid Conjugates)," The Journal of Biological Chemistry 247:2266-2271 (1972)
	*	Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," *Neuroscience* 76:1153-1158 (1997)
	*	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," Biochemistry 34:4068-4076 (1995)
	*	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," Chemistry & Biology 2:761-770 (1995)
	*	Groothuis and Levy, "The entry of antiviral and antiretroviral drugs into the central nervous system," Journal of NeuroVirology 3:387-400 (1997)
	*	Guerrier-Takada et al., "Metal Ion Requirements and Other Aspects of the Reaction Catalyzed by M1 RNA, the RNA Subunit of Ribonuclease P from *Escherichia coli*," Biochemistry 25:1509-1515 (1986)
	*	Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," Cell 35:849-857 (1983)
	*	Guo and Collins, "Efficent *trans*-cleavage of a stem-loop RNA substrate by a ribozyme derived from *Neurospora* VS RNA," EMBO J. 14:368-376 (1995)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Habus et al., "A Mild and Efficient Solid-Support Synthesis of Novel Oligonucleotide Conjugates," Bioconjugate Chem. 9:283-291 (1998)
	*	Hagihara et al., "Widespread gene transfection into the central nervous system of primates," Gene Therapy 7:759-763 (2000)
	*	Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," *Antisense & Nucleic Acid Drug Development* 9:25-31 (1999)
	*	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," Biochemistry 28:4929-4933 (1989)
	*	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," Nucleic Acids Research 18:299-304 (1990)
	*	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," RNA 1:210-218 (1995)
	*	Hartmann et al., "Spontaneous and Cationic Lipid-Mediated Uptake of Antisense Oligonucleotides in Human Monocytes and Lymphocytes," The Journal of Pharmacology and Experimental Therapeutics 285:920-928 (1998)
	*	Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus," Gene 82:43-52 (1989)
	*	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," Nature 334:585-591 (1988)
	*	Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," Biochemistry 34:15813-15828 (1995)
	*	Herrlinger et al., "HSV-1 Vectors for Gene Therapy of Experimental CNS Tumors," Methods Mol. Med. 35:287-312 (2000)
	*	Herschlag and Cech, "Catalysis of RNA Cleavage by the *Tetrahymena thermophila* Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," Biochemistry 29:10159-10171 (1990)

EXAMINER	DATE CONSIDERED
	11-07-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

		*	Herschlag and Cech, "Catalysis of RNA Cleavage by the *Tetrahymena thermophila* Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," Biochemistry 29:10172-10180 (1990)
		*	Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," Biochemistry 33:3374-3385 (1994)
		*	Hertel et al., "Numbering System for the Hammerhead," Nucleic Acids Research 20:3252 (1992)
		*	Ho et al., "Antisense Oligonucleotides for Target Validation in the CNS," Current Opinion in Molecular Therapeutics 1:336-343 (1999)
		*	Hudson et al., "Cellular Delivery of Hammerhead Ribozymes Conjugated to a Transferrin Receptor Antibody," Int'l Jour. of Pharmaceutics 182:49-58 (1999)
		*	International Search Report for PCT/US02/17674, Filed May 29, 2002
		32.	International Search Report for PCT/US03/05022 mailed January 6, 2005
		33.	International Search Report for PCT/US2004/016390 mailed March 31, 2005
n		34.	International Search Report for PCT/US2004/027403 mailed July 12, 2005
		35.	International Search Report for PCT/US2004/030488 mailed January 12, 2005
		*	International Search Report for PCT/US96/17480, Filed October 25, 1996
		*	Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," Biochemical and Biophysical Research Communication 214(2):403-409 (1995)
		*	Jaeger et al., "Improved Predictions of Secondary Structures for RNA," Proc. Natl. Acad. Sci. USA 86:7706-7710 (1989)
		*	Jarvis et al., "Optimizing the Cell Efficacy of Synthetic Ribozymes," Journal of Biological Chemistry 271:29107-29112 (1996)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Jaschke et al., "Synthesis and Properties of Oligodeoxyribonuclotide-polyethylene Glycol Conjugates," Nucleic Acids Research 22:4810-4817 (1994)
	*	Jaschke, "Oligonucleotide-Poly(ethylene glycol) Conjugates: Synthesis, Properties, and Application," American Chemical Society 680:265-283 (1997)
	*	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," Nucleic Acids Research 17:1371-1377 (1989) (also referred to as Jefferies)
	*	Jellinek et al., "Inhibitions of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry 33:10450-10456 (1994)
	36.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells, 18:307-319 (2000)
	*	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," Genes & Development 7:130-138 (1993)
	*	Joyce et al., "Amplification, mutation and selection of catalytic RNA," Gene 82:83-87 (1989)
	*	Joyce, "Directed Molecular Evolution," Scientific American 267:90-97 (1992)
	*	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of *Tetrahymena*," Proc. Natl. Acad. Sci. USA 84:8788-8792 (1987)
	*	Knitt et al., "ph Dependencies of the *Tetrahymena* Ribozyme Reveal an Unconvential Origin of an Apparent pK_a," Biochemistry 35:1560-1570 (1996)
	*	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisistsed; the NIH rule," Nucleic Acids Research, 26(18):4116-4120 (1998).
	*	Kronenwett et al., "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset," Blood 91:852-862 (1998)
	*	Kumar and Ellington, "Artificial evolution and natural ribozymes," FASEB J. 9:1183-1195 (1995)

EXAMINER	DATE CONSIDERED
Jonathan C. Good-Ford	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Kunath et al., "The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice.," Medline (Pharm Res.) 19(6): 810-817 (6/1/2002)
	37.	Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," *Genes and Development*, 14(15):1933-1944 (2000)
	*	Kuwabara et al., "Allosterically Controllable Ribozymes with Biosensor Functions," Current Opinion in Chem. Biol. 4:669-677 (2000)
	*	Lee et al., "Enhancing the Catalytic Repertoire of Nucleic Acids: A Systematic Study of Linker Length and Rigidity," Nucleic Acids Research 29:1565-1573 (2001)
	38.	Leifer et al., "Heterogeneity in the Human Response to Immunostimulatory CpG Oligodeoxynucleotides," *Journal of Immunotherapy*, 26(4):313-319 (2003)
	*	Lendlein et al., "Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications," *Science*, 296, 1673-1676 (2002)
	*	Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage λ burst size," Nucleic Acids Research 24:835-842 (1996)
	*	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the *Tetrahymena* Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," Biochemistry 34:14394-14399 (1995)
	*	Lichner et al., "Double-stranded RNA-binding proteins could suppress RNA interference-mediated antiviral defences," *Journal of General Virology*, 84, 975-980 (2003)
	*	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993)
	*	~~Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993)~~ dup
	*	Limbach et al., "Summary: the modified nucleosides of RNA," Nucleic Acids Research 22(12):2183-2196 (1994)

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," *J. Am. Chem. Soc.* 120:8531-8532 (1998)
	*	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," Biochemical and Biophysical Research Communications, 281, 639-644 (2001)
	*	Lin et al., "Policing rogue genes," Nature, 402, 128-129 (1999)
	*	Lisziewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," Proc. Natl. Acad. Sci. U.S.A. 90:8000-8004 (1993)
	*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," J. Biol. Chem. 270(42):24864-24870 (1995)
	*	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," Proc. Natl. Acad. Sci. USA 91:6977-6981 (1994)
	39.	Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF an VEGFR2 Down Regulation in Xenograft Models," *Cancer Gene Therapy,* 10, Suppl. 1, S4-S5 (2003)
	*	Ma and Wei, "Enhanced Delivery of Synthetic Oligonucleotides to Human Leukaemic Cells by Liposomes and Immunoliposomes," Leukemia Research 20:925-930 (1996)
	*	Maher et al., "Kinetic Analysis of Oligodeoxyribonucleotide-Directed Triple-Helix Formation on DNA," *Biochemistry* 29:8820-8826 (1990)
	*	McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," RNA 2:395-403 (1996)
	*	McLaren, "Vascular Endothelial Growth Factor and Endometriotic Angiogenesis," Human Reproduction Update 6:45-55 (2000)
	*	Michel and Westhof, "Slippery substratrates," Nat. Struct. Biol. 1:5-7 (1994)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-736 (400/134)	Serial No. 10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Michel et al., "Structure and Activities of Group II Introns," Annu. Rev. Biochem. 64:435-461 (1995)
	*	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," Biochemistry 34:2965-2977 (1995)
	*	Millauer, "High Affintiy VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," Cell 72:835-846 (1993)
	*	Milligan and Uhlenbeck, "Synthesis of Small RNAs Using T7 RNA Polymerase," Methods Enzymol. 180:51-62 (1989)
	*	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," *Nature Biotechnology* 15:537-541 (1997)
	*	Mitra et al., "A mammalian 2-5A system functions as an antiviral pathway in transgenic plants," Proc. Natl. Acad. Sci. USA 93:6780-6785 (1996)
	*	Mohr et al., "A tyrosyl-tRNA synthetase can function similarly to an RNA structure in the *Tetrahymena* ribozyme," Nature 370:147-150 (1994)
	*	Mori et al., "Inhibition of Chorodial Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secretable Endostatin," American Journal of Pathology, 159(1), 313-320 (2001)
	*	Morris et al., "A New Peptide Vector for Efficient Delivery of Oligonucleotides into Mammalian Cells," Nucleic Acids Research 25:2730-2736 (1997)
	*	Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," Critical Reviews in Oncogenesis 7:151-190 (1996)
	*	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," Biochemistry 33:1271-1277 (1994)
	*	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," Ann. Rev. Biochem. 44:273-293 (1975)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Neufeld et al., "Vascular Endothelial Growth Factor and Its Receptors," *Progress in Growth Factor Research* 5:89-97 (1994)
	*	Nomura et al., "Development of an Efficient Intermediate, α-[2-(Trimethylsilyl) ethoxy]-2-*N*-[2-trimethylsilyl)ethoxycarbonyl]folic Acid, for the Synthesis of Folate (γ)-Conjugates, and Its Application to the Synthesis of Folate-Nucleoside Conjugates," J. Org. Chem. 65:5016-5021 (2000)
	*	Orgel, "Selection *in vitro*," Proc. R. Soc. London B. 205:435-442 (1979)
	*	Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the Rnase P and pre-tRNA," Proc. Natl. Acad. Sci. USA 92:12510-12514 (1995)
	*	Parry *et al.* 1999. "Bioactivity of anti-angiogenic ribozymes targeting *Flt*-1 and *KDR* mRNA," Nucleic Acid Res. 27:2569-77.
	*	Peel and Klein, "Adeno-associated virus vectors: activity and applications in the CNS," Journal of Neuroscience Methods 98:95-104 (2000)
	*	Perrotta and Been, "A pseudoknot-like structure required for efficeint self-cleavage of hepatitis delta virus RNA," Nature 350:434-436 (1991)
	*	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," Biochemistry 31:16-21 (1992)
	*	Peterson et al., "Future Prospects of Gene Therapy for Treating CNS Diseases," Central Nervous System Diseases Chapter 24:485-508 (2000)
	*	Pierce et al., "Regulation of Vascular Endothelial Growth Factor by Oxygen in a Model of Retinopathy of Prematurity," Arch Ophthalmol 114:1219-1228 (1996)
	*	Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," *Pharmacol Ther.* 78:55-113 (1998)
	*	Plouët et al., "Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells," *The EMBO Journal* 8:3801-3806 (1989)
	*	Praseuth et al., "Triple helix formation and the antigene for sequence-specific control of gene expression," *Biochimica et Biophysica Acta* 1489:181-206 (1999)

EXAMINER	DATE CONSIDERED 11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," Nucleic Acids Research 21:4253-4258 (1993)
	*	Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," Biochemistry 33:2716-2725 (1994)
	*	Quereda et al., "Individual and Combined Effects of Triptoreline and Gestrinone on Experimental Endometriosis in Rats," European Obstetrics & Gynecology and Reproductive Biology 67:35-40 (1996)
	*	Randall et al., "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs," *PNAS*, 100, 235-240 (2003)
	*	Robertson et al., "Purification and Properties of a Specific *Escherichia coli* Riobnuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," J. Biol. Chem. 247:5243-5251 (1972)
	*	Robinson et al., "Oligodeozynucleotides Inhibit Retinal Neovascularization in a Murine Model of Proliferation Retinopathy," Proc. Natl. Acad. Sci. USA 93: 4851- 4856 (1996)
	*	Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," Aids Research and Human Retroviruses 8:183-189 (1992)
	*	Ruoslahti, "RGD and Other Recognition Sequences for Integrins," Annu. Rev. Cell Dev. Biol. 12:697-715 (1996)
	*	Salo et al., "Aminooxy Functionalized Oligonucleotides: Preparation, On-Support Derivatization, and Postsynthetic Attachment to Polymer Support," Bioconjugate Chem. 10:815-823 (1999)
	*	Sanghvi et al., "Improved Process for the Preparation of Nucleosidic Phosphoramidites Using a Safer and Cheaper Activator," Organic Process Res. & Dev. 4:175-181 (2000)
	*	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," Proc. Natl. Acad. Sci. USA 94:4262-4266 (1997)

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Santoro et al., "Mechanism and Utility of an RNA-Cleaving DNA Enzyme," *Biochemistry* 37:13330-13342 (1998)
	*	Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," *J. Am. Chem. Soc.* 122:2433-2439 (2000)
	*	Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In Neurospora Mitochondria," Cell 61:685-696 (1990)
	*	Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a *Neurospora* Mitochondrial Plasmid Transcript," Proc. Natl. Acad. Sci. USA 88:8826-8830 (1991)
	*	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," *The Journal of Biological Chemistry* 274:21783-21789 (1999)
	*	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," Nucleic Acids Research 24:573-581 (1996)
	*	Schwarze et al., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse," Science 285:1569-1572 (1999)
	*	Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," Cell 81:991-1002 (1995)
	*	Shalaby *et al.*, "Failure of Blood-island Formation and Vasculogenesis in Flk-1-deficient Mice," 1995 *Nature* 376, 62
	*	Sharkey et al., "Vascular Endothelial Growth Factor Expression in Human Endometrium is Regulated by Hypoxia," The Journal of Clinical Endocrinology & Metabolism 85:402-409 (2000)
	*	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (*flt*) closely related to the *fms* family," Oncogene 5:519-524 (1990)
	*	Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric Oligonucleotides," *Methods in Enzymology* 313:522-533 (1999)

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	40.	Snyder et al., "Defining Genes in the Genomics Era," *Science*, 300, 258-260 (2003)
	*	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" Science 261:1004-1288 (1993)
	*	Stein et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," Antisense & Nucleic Acid Drug Development 7:151-157 (1997)
	*	Stoeckemann et al., "Effects of the Progesterone Antagonists Onapristone (ZK 98 299) and ZK 136 799 on Surgically Induced Endometriosis in Intact Rats," Human Reproduction 10:3264-3271 (1995)
	*	Strobel and Dervan, "Site-Specific Cleavage of a Yeast Chromosome by Oligonucleotide-Directed Triple-Helix Formation," *Science* 249:73-75 (1990)
	*	Strobel et al., "Exocyclic Amine of the Conserved G·U Pair at the Cleavage Site of the *Tetrahymena* Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," Biochemistry 35:1201-1211 (1996)
	*	Strobel et al., "Minor Groove Recognition of the Conserved G·U Pair at the *Tetrahymena* Ribozyme Reaction Site," Science 267:675-679 (1995)
	*	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," Nature 371:619-622 (1994)
	*	Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," Cell 63:601-608 (1990)
	*	Szostak and Ellington, "Ch. 20 - In Vitro Selection of Functional RNA Sequences," in The RNA World, edited by Gesteland and Atkins, Cold Spring Harbor Laboratory Press, pp. 511-533 (1993)
	*	Szostak, "*In Vitro* Genes," TIBS 17:89-93 (1993)
	*	Takeshita *et al.*, "Therapeutic Angiogenesis: A Single Intraarterial Blous of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," 1995 *J. Clin. Invest.* 93, 662

EXAMINER	DATE CONSIDERED 11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," RNA 3:914-925 (1997)
	*	Terman et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," pp 1677-1683 (1991)
	*	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," Proc. Natl. Acad. Sci. USA 90:1300-1304 (1993)
	*	Uhlenbeck, "A Small Catalytic Oligoribonucleotide," Nature 328:596-600 (1987)
	*	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," Chemical Reviews 90:544-584 (1990)
	*	Usman et al., "Hammerhead ribozyme engineering," Current Opinion in Structural Biology 1:527-533(1996)
	*	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by *in Vitro* Selection," Biochemistry 36:6495-6501 (1997)
	*	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth," *The Journal of Biological Chemistry* 265:19461-19466 (1990)
	*	Wang et al., "Delivery of Antisense Oligodeoxyribonucleotides Against the Human Epidermal Growth Factor Receptor into Cultured KB Cells with Liposomes Conjugated to Folate via Polyethylene Glycol," Proc. Natl. Acad. Sci. USA 92:3318-3322 (1995)
	*	Warashina, et al., "Extremely High and Specific Activity of DNA Enzymes in Cells with a Philadelphia Chromosome, Chemistry & Biology, 6(4):237-250 (1999)
	*	Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," Nucleic Acids Research 23:2092-2096 (1995)
	*	Woolf et al., "Specificity of Antisense Oligonucleotides *in vivo*," Proc. Natl. Acad. Sci. USA 89:7305-7309 (1992)
	*	Wu and Kaufman, J. Biol. Chem., 272, 1921-1926 (1997)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Yang et al., "Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection," *PNAS*, 99, 21, 13825-13830 (2002)
	41.	Yonekura et al., "Placenta Growth Factor and Vascular Endothelial Growth Factor B and C Expression in Microvascular Endothelial Cells and Pericytes," *The Journal of Biological Chemistry*, 274(49):35172-35178 (1999)
	*	Yuan et al., "Targeted cleavage of mRNA by human RNase P," Proc. Natl. Acad. Sci. USA 89:8006-8010 (1992)
	*	Zabner et al., "Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Nasal Epithelia of Patients with Cystic Fibrosis," Cell 75:207-216 (1993)
	*	Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the *Tetrahymena* ribozyme," Nucleic Acids Research 24:854-858 (1996)
	*	Zaug et al., "The *Tetrahymena* Ribozyme Acts Like an RNA Restriction Endonuclease," Nature 324:429-433 (1986)
	*	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," Cell 83:529-538 (1995)
	*	Zinnen et al., "Chemically Modified siRNAa: Potential Anti-viral Hepatitis Therapeutics" (Abstract) March 2004
	42.	Autiero et al., "Role of P1GF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1," *Nature Medicine*, 9(7):936-942 (2003)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

OIPE JC151 JUL 22 2004 PATENT & TRADEMARK OFFICE

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	09/226,044	07/12/01	Hoffman et al.			
	*	10/151,116	05/17/02	Matulic-Adamic et al.			
	*	10/201,394	08/13/01	Vargeese et al.			
	*	10/287,949	11/04/02	Pavco			
	*	10/306,747	11/27/02	Pavco			
	*	10/427,160	04/30/03	Vargeese et al.			
	*	10/438,493	05/15/03	Pavco et al.			
	*	10/444,853	05/23/03	McSwiggen et al.			
	*	10/664,668	09/18/03	McSwiggen et al.			
	*	10/664,767	09/16/03	McSwiggen et al.			
	*	10/665,255	09/16/03	McSwiggen et al.			
	*	10/665,951	09/18/03	McSwiggen et al.			
	*	10/670,011	09/23/03	McSwiggen et al.			
	*	10/693,059	10/23/03	McSwiggen et al.			
	*	10/712,633	11/13/03	McSwiggen et al.			
	*	10/720,448	11/24/03	McSwiggen et al.			

EXAMINER	DATE CONSIDERED
	11/27/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	*	10/727,780	12/03/03	Vaish et al.			
	*	10/757,803	01/14/04	McSwiggen et al.			
	*	10/758,155	01/12/04	McSwiggen et al.			
	*	10/764,957	01/26/04	McSwiggen et al.			
	*	10/831,620	04/23/04	McSwiggen et al.			
	*	2001/0007666	07/12/01	Hoffman et al.			
	*	2002/0130430	09/19/02	Castor			
	*	2004/0037780	02/06/04	Parsons et al.			
	*	60/082,404	04/20/98	Thomspon et al.			
	*	60/334,461	11/30/01	Pavco			
	*	60/358,580	02/20/02	Beigelman et al.			
	*	60/363,124	03/11/02	Beigelman et al.			
	*	60/386,782	06/06/02	Beigelman et al.			
	*	60/393,796	07/03/02	McSwiggen et al.			
	*	60/399,348	07/29/02	McSwiggen et al.			
	*	60/402,996	08/13/02	Usman et al.			
	*	60/406,784	08/29/02	Beigelman et al.			
	*	60/408,378	09/05/02	Beigelman et al.			
	*	60/409,293	09/09/02	Beigelman et al.			

EXAMINER	DATE CONSIDERED
	11/27/07

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-H (400/134)	Serial No. 10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	*	60/440,129	01/15/03	Beigelman et al.			
	*	60/543,480	02/10/04	Jadhav et al.			

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	4,501,729	02/26/85	Boucher et al.			
	*	5,138,045	08/11/92	Cook et al.			
	*	5,214,136	05/25/93	Lin et al.			
	*	5,334,711	08/02/94	Sproat et al.			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,631,360	05/20/97	Usman et al.			
	*	5,670,633	09/23/97	Cook et al.			
	*	5,672,695	09/30/97	Eckstein et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,792,847	08/11/98	Buhr et al.			
	*	5,804,683	09/08/98	Usman et al.			
	*	5,814,620	09/29/98	Robinson et al.			

EXAMINER	DATE CONSIDERED
Ford	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	*	5,831,071	11/03/98	Usman et al.			
	*	5,854,038	12/29/98	Sullenger et al.			
	*	5,889,136	03/30/99	Scaringe et al.			
	*	5,898,031	04/27/99	Crooke			
	*	5,902,880	05/11/99	Thompson			
	*	5,998,203	12/07/99	Adamic et al.			
	*	6,001,311	12/14/99	Brennen			
	*	6,005,087	12/21/99	Cook et al.			
	*	6,008,400	12/28/99	Scaringe et al.			
	*	6,054,576	04/25/00	Bellon et al.			
	*	6,107,094	08/22/00	Crooke			
	*	6,111,086	08/29/00	Scaringe et al.			
	*	6,117,657	09/12/00	Usman et al.			
	*	6,146,886	11/14/00	Thompson et al.			
	*	6,153,737	11/28/00	Manoharan et al.			
	*	6,162,909	12/19/00	Bellon et al.			
	*	6,180,613	01/30/01	Kaplitt et al.			
	*	6,235,310	05/22/01	Wang et al.			
	*	6,248,878	06/19/01	Matulic-Adamic et al.			

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	*	6,300,074	10/09/01	Gold et al.			
	*	6,303,773	10/16/01	Bellon et al.			
	*	6,335,434	01/01/02	Guzaev et al.			
	*	6,353,098	03/05/02	Usman et al.			
	*	6,362,323	03/26/01	Usman et al.			
	*	6,395,713	05/28/02	Beigelman et al.			
	*	6,437,117	08/20/02	Usman et al.			
	*	6,447,796	09/10/02	Vook et al.			
	*	6,469,158	10/22/02	Usman et al.			
	*	6,476,205	11/05/02	Buhr et al.			
	*	6,506,559	01/14/03	Fire et al.			
	*	6,528,631	03/04/03	Cook et al.			
	*	6,565,885	05/20/03	Tarara et al.			
	*	6,582,728	06/24/03	Platz et al.			
	*	6,586,524	07/01/03	Sagara			
	*	6,592,904	07/15/03	Platz et al.			

FOREIGN PATENT DOCUMENTS

		Document	Date	Country	Class	Subclass	Translation

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

		Number					Yes	No
#	1.	4037501	08/03/00	AU (Kreutzer et al.)				
	2.	2,359,180	08/03/00	CA (Kreutzer et al.)				
	3.	1144623	08/03/00	EP (Kreutzer et al.)				
	4.	89/02439	03/23/89	WO (Arnold et al.)				
	5.	90/14090	11/29/90	WO (Gillespie et al.)				
	6.	91/03162	03/21/91	WO (Rossi et al.)				
	7.	92/07065	04/30/92	WO (Eckstein et al.)				
	8.	93/15187	08/05/93	WO (Usman et al.)				
	9.	93/23569	11/25/93	WO (Draper et al.)				
	10.	94/02595	02/03/94	WO (Sullivan et al.)				
	11.	94/01550	01/20/94	WO (Agrawal et al.)				
	12.	95/06731	03/09/95	WO (Usman et al.)				
	13.	95/11910	05/04/95	WO (Dudycz et al.)				
	14.	96/10390	04/11/96	WO (Ansell et al.)				
	15.	96/10391	04/11/96	WO (Choi et al.)				
	16.	96/10392	04/11/96	WO (Holland et al.)				
	17.	96/18736	06/20/96	WO (Beigelman et al.)				
	18.	97/26270	07/24/97	WO (Wincott et al.)				

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

* The PTO did not receive the following listed item(s) 4037501

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	19.	98/13526	04/02/98	WO (Woolf et al.)				
	20.	99/07409	02/18/99	WO (Deschamps de Pailette et al.)				
	21.	99/14226	03/25/99	WO (Wengel et al.)				
	22.	99/31262	06/24/99	WO (Barry et al.)				
	23.	99/32619	07/01/99	WO (Fire et al.)				
	24.	99/49029	09/30/99	WO (Graham et al.)				
	25.	99/53050	10/21/99	WO (Waterhouse et al.)				
	26.	99/54459	10/28/99	WO (Thompson et al.)				
	27.	99/61631	12/02/99	WO (Heifetz et al.)				
	28.	00/01846	01/13/00	WO (Plaetinck et al.)				
	29.	00/44895	08/03/00	WO (Kreutzer et al.)				
	30.	00/44914	08/03/00	WO (Li et al.)				
	31.	00/49035	08/24/00	WO (Sheen)				
	32.	00/53722	09/14/00	WO (O'Hare et al.)				
	33.	00/63364	10/26/00	WO (Pachuk et al.)				
	34.	00/66604	11/09/00	WO (Wengel et al.)				
	35.	01/04313	01/18/01	WO (Satishchandran et al.)				
	36.	01/29058	04/26/01	WO (Mello et al.)				
	37.	01/36646	05/25/01	WO (Zernicka-Goetz et al.)				

EXAMINER	DATE CONSIDERED 11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	38.	01/38551	05/31/01	WO (Grossniklaus et al.)				
	39.	01/42443	06/14/01	WO (Churikov et al.)				
	40.	01/49844	07/12/01	WO (Driscoll et al.)				
	41.	01/53475	07/26/01	WO (Cogoni et al.)				
	42.	01/68836	09/20/01	WO (Beach et al.)				
	43.	01/70944	09/27/01	WO (Honer et al.)				
	44.	01/70949	09/27/01	WO (Graham et al.)				
	45.	01/72774	10/04/01	WO (Deak et al.)				
	46.	01/75164	10/11/01	WO (Tuschl et al.)				
	47.	01/92513	12/06/01	WO (Arndt et al.)				
	48.	01/96584	12/20/01	WO (Mushegian et al.)				
	49.	02/055692	07/18/02	WO (Kreutzer et al.)				
	50.	02/055693	07/18/02	WO (Kreutzer et al.)				
	51.	02/22636	03/21/02	WO (Bennett et al.)				
	52.	02/38805	05/15/02	WO (Echeverri et al.)				
	53.	02/44321	06/06/02	WO (Tuschl et al.)				
	54.	02/096927	12/05/02	WO (Pavco)				
	55.	03/24420	03/27/03	WO (Alheim et al.)				
	56.	03/46185	06/05/03	WO (Wang et al.)				

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	

	57.	03/47518	06/12/03	WO (Wang et al.)				
	58.	PCT/US02/15876	05/20/02	Beigelman et al.				
	59.	PCT/US02/17674	05/29/02	WO (Pavco et al.)				
	60.	PCT/US03/05022	02/20/03	WO (McSwiggen et al.)				
	61.	PCT/US03/05028	02/20/03	McSwiggen et al.				
	62.	PCT/US03/05346	02/20/03	McSwiggen et al.				
	63.	WO 03/064625	02/03/03	WO (Woolf et al.)				
	64.	WO 03/064626	02/03/03	WO (Woolf et al.)				
	65.	WO 03/030989	04/17/03	WO (Behar et al.)				
	66.	WO 03/043689	05/03/03	WO (Behar et al.)				
	67.	WO 04/013280	05/26/03	WO (Davidson et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	68.	Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," *Current Medicinal Chemistry,* 8, 1189-1212 (2001)
	69.	Aiello et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders," The New England Journal of Medicine 331(22):1480-1487 (1994)
	70.	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," Trends Cell Biol. 2:139-144 (1992
	71.	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," Nucleic Acids Research 26:4910-4916 (1998)

EXAMINER	DATE CONSIDERED
Judith L. Flynn-Ford	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-H (400/134)	Serial No. 10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	72.	Allshire, "RNAi and Heterochromatin - A Hushed-up Affair," Science 297:1818-1819 (2002)
	73.	Andrews and Faller, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," Nucleic Acids Research 19:2499 (1991)
dup see IDS 7-22-04	74.	Autiero et al., "Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1," *Nature Medicine*, 9:936-943 (2003)
	75.	Baenziger and Fiete, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," Cell 22:611-620 (1980)
	76.	Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent α1(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene," Molecular and Cellular Biology, 274-283 (1999)
	77.	Bannai et al., "Effect of Injection of Antisense of Oligodeoxynucleotides of GAD Isozymes into Rat Ventromedial Hypothalamus on Food Intake and Locomotor Activity," Brain Research 784:305-315 (1998)
	78.	Bannai et al., "Water-absorbent Polymer as a Carrier for a Discrete Deposit of Antisense Oligodeoxynucleotides in the Central Nervous System," Brain Research Protocols 3:83-87 (1998)
	79.	Bass, "The short answer," Nature 411:428-429 (2001)
	80.	Bass, "Double-Stranded RNA as a Template for Gene Silencing," *Cell*, 101, 235-238 (2000)
	81.	Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," Tetrahedron 49:1925-1963 (1993)
	82.	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," The Journal of Biological Chemistry 270:25702-25708 (1995)
	83.	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," Nucleosides & Nucleotides 16:951-954 (1997)
	84.	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," Bioconjugate Chem. 8:204-212 (1997)

EXAMINER	DATE CONSIDERED
/John L. Ford/	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	85.	Berkman et al., "Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms," The Journal of Clinical Investigation, Inc. 91:153-159 (1993)
	86.	Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," Nature 409:363-366 (2001)
	87.	Bettinger et al., "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," *Bioconjugate Chem.*, 10, 558-561 (1999)
	88.	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," Journal of Pharmaceutical Sciences 87:1308-1315 (1998)
	89.	Boado, "Antisense drug delivery through the blood-brain barrier," Advanced Drug Delivery Reviews 15:73-107 (1995)
	90.	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," Biotechnology and Bioengineering (Combinatorial Chemistry) 61:33-45 (1998)
	91.	Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," J Neurosurg 88:734-742 (1998)
	92.	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," Reviews in Molecular Biotechnology 74:5-13 (2000)
	93.	Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," Cornea 4:35-41 (1985/1986)
	94.	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," Biochemistry 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
	95.	Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," Bioorganic & Medicinal Chemistry 5:1999-2010 (1997)

EXAMINER	DATE CONSIDERED
[signature]	11-22-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	96.	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," Methods in Enzymology 211:3-19 (1992)
	97.	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," Nucleic Acids Research 20:4581-4589 (1992)
	98.	Chiu et al., "siRNA function in RNAi: A chemical modification analysis," RNA, 9:1034-1048 (2003)
	99.	Choi et al., "Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a Gene Transfer Vector *in vitro*," *Bull. Korean Chem. Soc.*, 22, 46-52 (2001)
	100.	Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," J. Biol. Chem. 269:25856-25864 (1994)
	101.	Clark and Yoria, "Ophthalmic Drug Discovery," *Nature*, 2, 448-459 (2003)
	102.	Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR:Structure and Function," *J. Interferon & Cytokine Res.*, 17, 503-524 (1997)
	103.	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," J. Am. Chem. Soc. 113:6324-6326 (1991)
	104.	Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," The Journ. of Biol. Chem. 257:939-945 (1982)
	105.	Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration," Clinical Cancer Research 5:2330-2337 (1999)
	106.	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," Trends In Genetics 12:510-515 (1996)
	107.	Detmar et al., "Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis," J. Exp. Med. 180:1141-1146 (1994)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	108.	Diebold et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells*," *The Journal of Biological Chemistry*, 274, 19087-19094 (1999)
	109.	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," Journal of Virology 66:1432-1441 (1992)
	110.	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," Nucleic Acids Research 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]
	111.	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," Biopolymers 48:39-55 (1998)
	112.	Economides et al., Cytokine traps: multi-componetnt, high-affinity blockers of cytokine action," *Nature Medicine*, 9, 1, 47-52 (2003)
	113.	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," Nature 411:494-498 (2001)
	114.	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila Melanogaster Embryo Lysate," The EMBO Journal 20:6877-6888 (2001)
	115.	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," Genes and Development 15:188-200 (2001)
	116.	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in Delivery Strategies for Antisense Oligonucleotide Therapeutics, edited by Akhtar, CRC Press, pp. 17-220 (1995)
	117.	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," Proc. Natl. Acad. Sci. USA 87:6743-6747 (1990)
	118.	Emerich et al., "Biocompatability of Poly (DL-Lactide-co-Glycolide) Microshperes Implanted Into the Brain," Cell Transplantation 8:47-58 (1999)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	119.	Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and *In Vivo*, Using β-Cyclodextrin-Adamantane-Oligonucleotide Conjugates," *Anitsense Nuc. Acid Drug Dev.*, 10:469-478 (2000)
	120.	Erbacher et al., "Transfection and physical properties of various sacccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI), *The Journal of Gene Medicine*, 1, 210-222 (1999) [sometimes incorrectly cited as pages 1-18]
	121.	Fava et al., "Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue," J. Exp. Med. 180:341-346 (1994)
	122.	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," J. Am. Chem. Soc. 113:4000-4002 (1991)
	123.	Filleur et al., "SiRNA-mediated Inhibition of Vascular Endothelial Growth Factor Severely Limits Tumor Resistance to Antiangiogenic Thrombospondin-1 and Slows Tumor Vascularization and Growth," *Cancer Research*, 63, 3919-3922 (2003)
	124.	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis Elegans," Nature 391:806-811(1998)
	125.	Fire, "RNA-triggered Gene Silencing," TIG 15:358-363(1999)
	126.	Folkman et al., "Long-term Culture of Capillary Endothelial Cells," Proc. Natl. Acad. Sci. USA 76:5217-5221 (1979)
	127.	Folkman, Judah, "Tumor Angiogenesis," Advances in Cancer Research 43:175-203 (1985)
	128.	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," Proc. Natl. Acad. Sci. USA 83:9373-9377 (1986) [sometimes referred to as Frier]
	129.	Furgeson et al., "Modified Linear Polyethylenimine—Cholesterol Conjugates for DNA Complexation," *Bioconjugate Chem.*, 14, 840-847 (2003)
	130.	Futami et al., "Induction fo apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," *Nucleic Acids Research Supplement*, 251-252 (2002)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	131.	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," Nucleic Acids Research 21:2867-2872 (1993)
	132.	Genbank Accession No. AF020393
	133.	Genbank Accession No. AF022375
	134.	Genbank Accession No. AF024710
	135.	Genbank Accession No. AF035121
	136.	Genbank Accession No. AF063657
	137.	Genbank Accession No. AF063658
	138.	Genbank Accession No. AF092125
	139.	Genbank Accession No. AF092126
	140.	Genbank Accession No. AF092127
	141.	Genbank Accession No. AF095785
	142.	Genbank Accession No. AF098331
	143.	Genbank Accession No. AF437895
	144.	Genbank Accession No. AF468110
	145.	Genbank Accession No. AF486837
	146.	Genbank Accession No. AH006909
	147.	Genbank Accession No. AJ000185
	148.	Genbank Accession No. AJ010438
	149.	Genbank Accession No. AY047581

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

JG	150.	Genbank Accession No. D89630
	151.	Genbank Accession No. E13256
	152.	Genbank Accession No. E13332
	153.	Genbank Accession No. E14000
	154.	Genbank Accession No. E14233
	155.	Genbank Accession No. E15156
	156.	Genbank Accession No. E15157
	157.	Genbank Accession No. NM_002019
	158.	Genbank Accession No. NM_002020
	159.	Genbank Accession No. NM_002253
	160.	Genbank Accession No. NM_003376
	161.	Genbank Accession No. NM_003377
	162.	Genbank Accession No. NM_004469
	163.	Genbank Accession No. NM_005429
	164.	Genbank Accession No. U01134
	165.	Genbank Accession No. X62568
	166.	Genbank Accession No. X94216
	167.	Genbank Accession No. Y08736
	168.	Godbey et al., "Poly(ethylenimine) and its role in gene delivery," *Journal of Controlled Release*, 60, 149-160 (1999)

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	

	169.	Godbey et al., "Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery," *Proc. Natl. Acad. Sci. USA*, 96, 5177-5181 (1999)
	170.	Gold et al., "Diversity of Oligonucleotide Functions," Annu. Rev. Biochem. 64:763-797 (1995)
	171.	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," Bioconjugate Chem. 10:1068-1074 (1999)
	172.	Good et al., "Expression of small, therapuetic RNAs in human nuclei," Gene Therapy 4:45-54 (1997)
	173.	Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," Diabetologia 36:282-291 (1993)
	174.	Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," Science 297:2232-2237 (2002)
	175.	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," Science, 286, 950-952 (1999)
	176.	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in Drosophila Cells," Nature 404:293-296 (2000)
	177.	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," Antisense and Nucleic Acid Drug Development, 13:83-105 (2003)
	178.	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," Science 287:820-825 (2000)
	179.	Hofland and Huang, "Formulation and Delivery of Nucleic Acids," Handbook of Exp. Pharmacol. 137:165-192 (1999)
	180.	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," VCH, 331-417 (1995)
	181.	Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," Science 297:2056-2060 (2002)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	182.	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA," Science 293:834-838 (2001)
	183.	International Search Report for PCT/US03/05028 mailed October 17, 2003
	184.	International Search Report for PCT/US03/05346 mailed October 17, 2003
	185.	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," Chem. Pharm. Bull. 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
	186.	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," Science 229:345-352 (1985)
	187.	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," Tetrahedron Letters 34:301-304 (1993) (sometimes mistakenly referred to as Jschke)
	188.	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," Clinical Chemistry 45:1628-1650 (1999)
	189.	Jenuwein, "An RNA-Guided Pathway for the Epigenome," Science 297:2215-2218 (2002)
	190.	Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," Fundam. Clin. Pharmacol. 13:16-26 (1999)
	191.	Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the $GABA_A$ Receptor $\gamma 2$ Subunit," Euro. Jour. of Pharmacology 340:153-160 (1997)
	192.	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," Tetrahedron Letters 39:1131-1134 (1998)
	193.	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," Antisense Research & Development 2:3-15 (1992)

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	194.	Kaspareit-Rittinghausen et al., "Animal Model of Human Disease: Hereditary Polycystic Kidney Disease," Amer. Journ. of Pathology 139:693-696 (1991)
	195.	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993)
	196.	Koch et al., "Vascular Endothelial Growth Factor," Journal of Immunology 152:4149-4156 (1994)
	197.	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," Reviews in Molecular Biotechnology 74:27-38 (2000)
	198.	Kwak et al., "VEGF Is Major Stimulator in Model of Choroidal Neovascularization," Investigative Ophthalmology & Visual Science, 41(10), 3158-3164 (2000)
	199.	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," Chemical Reviews 95:2601-2627 (1995)
	200.	Lasic and Papahadjopoulos, "Liposomes Revisited," Science 267:1275-1276 (1995)
	201.	Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," ACS Symposium Series 752:184-192 (2000)
	202.	Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," Glyconjugates J. 4:317-328 (1987)
	203.	Lee et al., "Expression of Small Interfering RNA's Targeted Against HIV-1 rev Transcripts in Human Cells," Nature Biotechnology 19:500-505 (2002)
	204.	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," *Biochemical and Biophysical Research Communications,* 295, 744-748 (2002)
	205.	Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," Journal of Ocular Pharmacology 10:273-281 (1994)

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	206.	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α-Lactalbumin mRNA Levels in C1271 Mouse," EMBO J. 11:4411-4418 (1992)
	207.	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993)
	208.	Limbach et al., "Summary: the modified nucleosides of RNA," Nucleic Acids Research 22(12):2183-2196 (1994)
	209.	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," J. Am. Chem. Soc. 120:8531-8532 (1998)
	210.	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," *Biochemical and Biophysical Research Communications,* 281, 639-644 (2001)
	211.	Lin et al., "Policing Rogue Genes", Nature 402:128-129 (1999)
	212.	Lisziewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," Proc. Natl. Acad. Sci. U.S.A. 90:8000-8004 (1993)
	213.	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," J. Biol. Chem. 270(42):24864-24870 (1995)
	214.	Loakes, "The Applications of Universal DNA Base Analogues," Nucleic Acids Research 29:2437-2447 (2001)
	215.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," Nucleic Acids Research 21:2585-2589 (1993)
	216.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," Biochemistry 32:1751-1758 (1993)
	217.	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," Cell 110:563-574 (2002)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	218.	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," Molecular Membrane Biology 16:129-140 (1999)
	219.	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" Nucleosides & Nucleotides 10:287-290 (1991)
	220.	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," Proc. Natl. Acad. Sci. USA 83:399-403 (1986)
	221.	McLaren et al., "Vascular Endothelial Growth Factor (VEGF) Concentrations are Elevated in Peritoneal Fluid of Women with Endometriosis," Human Reproduction 11:220-223 (1996)
	222.	McLaren et al., "Vascular Endothelial Growth Factor is Produced by Peritoneal Fluid Macrophages in Endometriosis and Is Regulated by Ovarian Steroids," J. Clin. Invest. 98:482-489 (1996)
	223.	McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," RNA 8:842-850 (2002)
	224.	Mesmaeker et al, "Novel Backbone Replacements for Oligonucleotides," American Chemical Society, pp. 24-39 (1994)
	225.	Millauer et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant," Letters to Nature 367:576-579 (1994)
	226.	Miller et al., "Vascular Endothelial Growth Factor/Vascular Permeability Factor is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model," American Journal of Pathology 145:574-584 (1994)
	227.	Miyagishi and Taira, "U6 Promoter-driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells," Nature Biotechnology 19:497-500 (2002)
	228.	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," Science 256:992-996 (1992)
	229.	Mori et al., "Inhibition of Chorodial Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secretable Endostatin," American Journal of Pathology, 159(1), 313-320 (2001)

EXAMINER	DATE CONSIDERED
Jonathan Ford	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	230.	Mori et al., "Pigment epithelium-derived factor inhibits retinal and choroidal neovacularization," Journal of Cellular Physiology, 118(2) 253-263 (2001)
	231.	Noonberg et al., In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," Nucleic Acids Research 22(14):2830-2836 (1994)
	232.	Norrby, "Angiogenesis: new aspects relating to its initiation and control," APMIA 105:417-437 (1997)
	233.	Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," Nature Medicine 1-6 (2002)
	234.	Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," Cell 107:309-321 (2001)
	235.	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," Nucleic Acids Symp. Ser. 27:15-16 (1992)
	236.	Ohno-Matsui, et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," *Animal Models* from the Departments of Ophthalmology and Neuroscience and Molecular Biology and Genetics, *Am. J. Pathology,* 160, 711-719 (2002)
	237.	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," Proc. Natl. Acad. Sci. USA 89:10802-10806 (1992)
	238.	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," Biochimica et Biophysica Acta 1238:86-90 (1995)
	239.	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," Biochemistry 30:9914-9921 (1991)
	240.	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell 79:315-328 (1994)

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	241.	Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," *AAPS PharmSci.*, 3 (3) article 21 (http://www.pharmsci.org) p. 1- 11 (2001)
	242.	Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," American Journal of Pathology 137:1243-1252 (1990)
	243.	Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localization in *Drosophila* Are Dependent on the RNAi Machinery," *Science,* 303, 669-672 (2004)
	244.	Pandey et al., "Role ov B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF-α-Induced Angiogenesis," Science 268:567-569 (1995)
	245.	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo," Proc. Natl. Acad. Sci. USA 92:5592-5596 (1995)
	246.	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," Molecular Cell 6:1077-1087 (2000)
	247.	Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," Laboratory Investigation 67:519-528 (1992)
	248.	Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," Nature Biotechnology 20:505-508 (2002)
	249.	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," Nature 344:565-567 (1990) (often mistakenly listed as Perrault)
	250.	Petersen et al., "Polyethylenimine-*graft*-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System, *Bioconjugate Chem.*, 13, 845-854 (2002)
	251.	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," Science 253:314-317 (1991)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	252.	Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," Proc. Natl. Acad. Sci. USA 92:905-909 (1995)
	253.	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gilomas in vivo," Nature 359:845-848 (1992)
	254.	Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," J. Med. Chem. 24:1388-1395 (1981)
	255.	Rajakumar et al., "Effects of Intrastriatal Infusion of D_2 Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," Synapse 26:199-208 (1997)
	256.	Reich et al., "Small Interfering RNA (siRNA) targeting *VEGF* effectively inhibits ocular neovascularization in a mouse model," *Molecular Vision*, 9, 210-216 (2003)
	257.	Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," Science 297:1831 (2002)
	258.	Reinhart et al., "MicroRNAs in Plants," Genes & Development 16:1616-1626 (2002)
	259.	Reynolds et al., "Rational siRNA designe for RNA intereference," *Nature Biotechnology*, 22, 3, 326-330 (2004)
	260.	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," J. Am. Chem. Soc. 113:5109-5111 (1991)
	261.	Saenger (ed), "Modified Nucleosides and Nucleotides; Nucleoside Di- and Triphosphates; Coenzymes and Antibiotics, (ch.7)" Principles of Nucleic Acid Structure 158-200 (1984)
	262.	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" Science 247:1222-1225 (1990)
	263.	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," Proc. Natl. Acad. Sci. USA 88:10591-10595 (1991)
	264.	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β-cyanoethyl protected ribonucleoside phosphoramidites," Nucl Acids Res. 18:5433-5441 (1990)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	265.	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 23:941-949 (1999) [sometimes cited by RPI as Prog Neuropsychopharmacol Biol Psychiatry 23:941-949, 1999
	266.	Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the Drosophila and Human RNAi Pathways," Molecular Cell 10:537-548 (2002)
	267.	Schwarz et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," Cell, 1115, 199-208 (2003)
	268.	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," Nucleic Acids Research 15:3113-3129 (1987)
	269.	Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," Cancer and Matastasis Reviews 12:303-324 (1993)
	270.	Shabarova et al., "Chemical ligation of DNA: The first non-enyzmatic assembly of a biologically active gene," Nucleic Acids Research 19:4247-4251 (1991)
	271.	Sharp, Philip A., "RNAi and Double-strand RNA", Genes and Development 13:139-141 (1999)
	272.	Sheehan et al., "Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides," *Nucleic Acids Research*, 31 (14), 4109-4118 (2003)
	273.	Shifren et al., "Ovarian Steroid Regulation of Vascular Endothelial Growth Factor in the Human Endometrium: Implications for Angiogenesis during the Menstrual Cycle and in the Pathogenesis of Endometriosis," The Journal of Clinical Endocrinology & Metabolism 81:3112-3118 (1996)
	274.	Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," J. Clin. Invest. 91:2235-2243 (1993)
	275.	Simantov et al., "Dopamine-Induced Apoptosis in Human Neuronal Cells: Inhibition by Nucleic Acids Antisense to the Dopamine Transporter," Neuroscience 74(1):39-50 (1996)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	276.	Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," Antisense & Nucleic Acid Drug Development 8:75-85 (1998)
	277.	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found" Molecular Biology, 286: 5441, p.886 (1999)
	278.	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," Science 262:1566-1569 (1993)
	279.	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc," Current Opinion in Molecular Therapeutics 2:100-105 (2000)
	280.	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences transcription vectors," Nucleic Acids Research 19:5125-5130 (1991)
	281.	Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," Cancer Research 54:4233-4237 (1994)
	282.	Thomas et al., "Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells," *PNAS*, 99, 14640-14645 (2002)
	283.	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," Nucleic Acids Research 23:2259-2268 (1995)
	284.	Turner et al., "Improved Parameters for Prediction of RNA Structure," Cold Spring Harbor Symposia on Quantitative Biology Volume LII, pp. 123-133 (1987)
	285.	Turner et al., " Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," J. Am. Chem. Soc. 109:3783-3785 (1987)
	286.	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," *Genes & Development* 13:3191-3197 (1999)

EXAMINER	DATE CONSIDERED
John L. Ford	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	287.	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," *Molecular Interventions*, 295, 3, 158-167 (2002)
	288.	Tuschl, "RNA Interference and Small Interfering RNAs," Chembiochem 2:239-245 (2001)
	289.	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," Proc. Natl. Acad. Sci. USA 96:7053-7058 (1999)
	290.	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," FEBS Letters 421:280-284 (1998)
	291.	Uhlmann et al., "Studies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation," Antisense & Nucleic Acid Drug Development 7:345-350 (1997)
	292.	Ui-Tei et al., "Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference," Nucleic Acids Research, 32, 3, 936-948 (2004)
	293.	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," TIBS 17:334-339 (1992)
	294.	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," Annual Reports in Medicinal Chemistry 30:285-294 (1995)
	295.	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an Escherichia coli Formylmethoionine tRNA," J. Am. Chem. Soc. 109:7845-7854 (1987)
	296.	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," Nucleic Acids Syposium Series 31:163-164 (1994)
	297.	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," Nucleic Acids Research 21:3249-3255 (1993)

EXAMINER	DATE CONSIDERED
	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	298.	Verdel et al., "RNAi-Mediated Targeting ofHeterochromatin by the RITS Complex, Science, 303, 672-676 (2004)
	299.	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," Annu. Rev. Biochem. 67:99-134 (1998)
	300.	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," Science 297:1833-1837 (2002)
	301.	Waterhouse, et al. "Virus Resistance and gene Silencing in Plants Can Be Induced by Simultaneous Expression of Sense and Antisense RNA" Proc. Natl. Acad. Sci. USA 99:13959-13964 (1998)
	302.	Weckbecker et al., "Intradermal angiogenesis in nude mice induced by human tumor cells or b-FGF," Angiogenesis Key Principles–Science–Technology–Medicine pp296-301 (1992)
	303.	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4+ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," Journal of Virology 65:5531-5534 (1994)
	304.	Wellstein and Czubayko, "Inhibition of Fibroblast Growth Factors," Breast Cancer Research and Treatment 38:109-119 (1996)
	305.	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," Nature Cell Biology 2:70-75 (2000)
	306.	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," Nucleic Acids Research 23(14):2677-2684 (1995)
	307.	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," Methods in Molecular Biology 74:59-69 (1997)
	308.	Woo et al., "Taxol Inhibits Progression of Congenital Polycystic Kindey Disease," Nature 368:750-753 (1994)
	309.	Wu and Wu, "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The Journ. of Biol. Chem. 262:4429-4432 (1987)

EXAMINER	DATE CONSIDERED 11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		02-742-H (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date: October 10, 2003	Group:

	310.	Wu et al., "Cardiac Defects and Renal Failure in Mice with Targeted Mutations in Pkd2," Nature Genetics 24:75-78 (2000)
	311.	Wu-Pong et al., "Nucleic Acid Drug Delivery, Part 2; Delivery to the Brain," _ 32-38 (1999)
	312.	Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," Published online: 29 June 2003, doi:10.1038/nbt843 (August 2003 Volume 21 Number 8 pp 885-890) (2003)
	313.	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993)
	314.	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," Cell 101:25-33 (2000)
	315.	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," Mol. Cell. Biol. 10:4529-4537 (1990)
	316.	Ziche et al., "Angiogenesis Can Be Stimulated or Repressed In Vivo by a Change in GM3:GD3 Ganglioside Ratio," Laboratory Investigation 67:711-715 (1992)

EXAMINER	DATE CONSIDERED
[signature]	11-27-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001